Listing of Ongoing Cancer Clinical Trials in the Sacramento Area

Winter 2007

I. Solid Tumors

1. Breast p.1
2. Central Nervous System p.3
3. Gastrointestinal p.3
4. Gynecologic p.4
5. Head & Neck p.5
6. Lung p.5
7. Melanoma p.7
8. Mesothelioma p.7
10. Sarcoma p.7
11. Urological p.8

II. Hematological Cancers

1. Leukemia p.8
2. Lymphoma p.9
3. Myeloma p.9

I. Solid Tumors

1. Breast Cancer

1. Phase III Randomized Study of Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (4 vs. 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial (contact: Tracy Miesen, UCD)

2. Randomized Phase III Study of Conventional Whole Breast Irradiation Versus Partial Breast Irradiation For Women With Stage 0, I, or II Breast Cancer (contact: Frances Lara, UCD)

3. Phase III Trial of Continuous Schedule AC + G vs. Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer (contact: Tracy Miesen, UCD; Kirsten Babski or Lori Ried, SCC)
4. Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer (contact: Tracy Miesen, UCD)

5. Phase III Trial Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (contact: Tracy Miesen, UCD, MHG)

6. Phase III, Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC to P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AP to PG) (contact: Kirsten Babski or Lori Ried, SCC)

7. Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer (contact: Kirsten Babski or Lori Ried, SCC)

8. Randomized Phase III Trial of Neoadjuvant Chemotherapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens (contact: Kirsten Babski or Lori Ried, SCC)

9. Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone Receptor Negative Breast Cancer (Contact: Rhoda Pineda, MGH)

10. Phase III, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy Regimens in Subjects with Previously Treated Metastatic Breast Cancer (Contact: Rhoda Pineda, MGH)

11. Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (Contact: Rhoda Pineda, MGH)

12. Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer (contact: Tracy Miesen, UCD; Kirsten Babski or Lori Ried, SCC)

13. Phase II, Multicenter, Open-Label, Single Arm Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with HER2+ Disease (contact: Kirsten Babski or Lori Ried, SCC)

14. Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients with Metastatic Breast Cancer (contact: Tracy Miesen, UCD)

15. Phase II Study of Goserelin Plus Anastrozole for the Treatment of Male Patients With Hormone-Receptor Positive Metastatic or Recurrent Breast Cancer (contact: Tracy Miesen, UCD)

16. Phase II Study of Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer (contact: Beverly Schroeder, UCD)

17. Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (contact: Kirsten Babski or Lori Ried, SCC)

18. Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node Negative Breast Cancer (contact: Kirsten Babski or Lori Ried, SCC)

19. Pilot Study of Radiofrequency Ablation of Early Invasive and In-Situ Breast Cancer (contact: Christina Bachman, UCD)

20. The TAILORx Trial: Program for the Assessment of Clinical Cancer Tests (PAACT-1): Trial Assigning Individualized Options for Treatment Endocrine Responsive Breast Cancer (contact: Kirsten Babski or Lori Ried, SCC)
21. Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer (contact: Denise Macias, UCD)
22. Serum Glycan Analysis in Breast Cancer  (contact: Beverly Schroeder, UCD)

Breast Cancer Web-Based Tutorial  (contact: Janet Keyzer, UCD)

2. Central Nervous System Tumors

1. Phase III Multicenter Study of Intratumoral/Interstitial Therapy with TransMID Compared to Best Standard of Care in Patients with Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme (contact: Tracy Liu, UCD)
2. Phase III Randomized, Double Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone (contact: Nancy Rudisill, UCD)
3. Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma (contact: Frances Lara, UCD)
4. Phase II Trial of Conformal Radiation Therapy for Pediatric Patients with Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated Supratentorial Ependymoma (contact: Tracy Liu, UCD)
5. Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low Grade Gliomas (contact: Frances Lara, UCD)
6. Concurrent Radiation and Temozolomide Followed by Temozolomide and Lomustine in the Treatment of High-Grade Gliomas (contact: Tracy Liu, UCD)
7. Neuroblastoma Biology Studies (contact: Tracy Liu, UCD)
8. Hepatoblastoma Biology Study and Tissue Bank - A Non-Therapeutic Study (contact: Tracy Liu, UCD)

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (contact: Christine Reed, UCD)
2. Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (contact: Christine Reed, UCD)
3. Phase III Multi-Center, Randomized Clinical Trial to Evaluate the Safety and Efficacy of Cofactor and 5-FU plus Bevacizumab vs. Leucovorin and 5-FU plus Bevacizumab as Initial Treatment for Metastatic Colorectal Cancer (contact: Rhoda Pineda, MGH)
4. Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (contact: Kirsten Babski or Lori Ried, SCC)
5. Randomized Phase II Trial of Neoadjuvant Combined Modality Therapy for Locally Advanced Rectal Cancer (contact: Frances Lara, UCD)
6. Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum (contact: Kirsten Babski or Lori Ried, SCC)

B. Esophageal Cancer

1. Phase II Trial with Molecular Correlates of Cetuximab Plus Cisplatin, Irinotecan and Thoracic Radiotherapy (TRT) for Locally Advanced (Non-Metastatic), Clinically Unresectable Esophageal Cancer. (contact: Christine Reed, UCD)

C. Gall bladder/ Bile duct Cancer

1. Phase II Study of Triapine in Combination with Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder (contact: Nicole Ekedahl, UCD)

D. Liver Cancer

1. Phase III Randomized Study of Postoperative Cisplatin, Vincristine, and Fluorouracil with or without Amifostine Versus Carboplatin and Cisplatin with or without Amifostine in Children with Hepatoblastoma (contact: Tracy Liu, UCD)

E. Pancreatic Cancer

1. Randomized Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Metastatic Pancreatic Carcinoma (contact: Joan Houston, UCD)

4. Gynecologic Cancers

A. Cervical Cancer

1. Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent or Persistent Carcinoma of the Cervix (contact: Frances Lara, UCD)

2. Phase III Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis (contact: Frances Lara, UCD)

3. Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-operative Patients with Either Endometrial or Cervical Carcinoma (contact: Frances Lara, UCD)

B. Ovarian/Peritoneal Cancer

1. Phase III Randomized Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xytox, Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (contact: Frances Lara, UCD)
2. **Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer (contact: Frances Lara, UCD; Kirsten Babski or Lori Ried, SCC)

3. Randomized Study of Tamoxifen Versus Thalidomide in Patients with Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, or Primary Peritoneal Carcinoma After First Line Chemotherapy (contact: Frances Lara, UCD)

4. **Clinical Protocol to Evaluate Glycans Analysis As a Diagnostic Test for Ovarian Cancer (contact: Frances Lara, UCD)**

C. **Uteral Cancer**

1. Phase III Randomized Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III and IV or Recurrent Endometrial Cancer (contact: Frances Lara, UCD)

4. **Head & Neck Cancer**

1. Phase III Randomized Trial of Concurrent Accelerated Radiation and Cisplatin vs. Concurrent Accelerated Radiation, Cisplatin and Cetuximab (C225) [Followed by Surgery for Selected Patients] For Stage III and IV Head and Neck Carcinomas (contact: Frances Lara, UCD)

5. **Lung Cancer**

1. Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer (contact: Beverly Schroeder, UCD)

2. **Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases (contact: Frances Lara, UCD)**

3. Phase III Randomized Trial of Cisplatin and Irinotecan Versus Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (contact: Brian Kuest, UCD, 916-734-3089; Kirsten Babski or Lori Ried, SCC)

4. **Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I, Non-Small Cell Lung Cancer (contact: Rhoda Pineda, MGH)**

5. Phase III Randomized, Double Blind, Placebo-Controlled Trial Comparing Bevacizumab Therapy with or without Erlotinib after Completion of Chemotherapy with Bevacizumab for the First Line Treatment of Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (contact: Rhoda Pineda, MGH; Kirsten Babski or Lori Ried, SCC)

6. **Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel (Taxotere) in Combination with ZD6474 versus Docetaxel (Taxotere) in Combination with Placebo in Patients with Locally Advanced or Metastatic (Stage IIIb-IV) Non-Small Cell Lung Cancer After Failure of 1st Line Anti-Cancer Therapy (contact: Kirsten Babski or Lori Ried, SCC)**

7. Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I, Non-Small Cell Lung Cancer (contact: Rhoda Pineda, MGH)
8. An Open-Label Phase II Study of Weekly Intravenous Hycamtin and Carboplatin as First-Line Treatment of Chemonaive Subjects with Extensive Small Cell Lung Cancer  (contact: Rhoda Pineda, MGH)

9. Phase III National Web-Based Randomized Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin and Thoracic Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer  (contact: Rhoda Pineda, MGH)

10. Phase II Study of Bortezomib (PS-341) for Patients With Advanced Bronchoalveolar Carcinoma  (contact: Beverly Schroeder, UCD)

11. Phase II Randomized Trial of Sequential Versus Concurrent Docetaxel and PS-341 in Previously Treated Non-Small Cell Lung Cancer  (contact: Joan Houston, UCD)

12. Phase II Study of the Halichondrin B Analog E7389 in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with a Taxane  (contact: Nicole Ekedahl, UCD)

13. Phase II Open-Label Study of Weekly Intravenous Hycamtin and Carboplatin as First-Line Treatment of Chemonaive Subjects with Extensive Small Cell Lung Cancer  (contact: Rhoda Pineda, MGH)

14. Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non-Small Cell Lung Cancer in Combination with Bevacizumab, Paclitaxel and Carboplatin Patients at High Risk of Bevacizumab-Associated Hemoptysis  (contact: Nicole Ekedahl, UCD)

15. Phase II Trial of BAY 43-9006 in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer  (contact: Brian Kuest, UCD)

16. Phase II Open Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients with Advanced Small-Cell Lung Cancer  (contact: Frances Lara, UCD)

17. Phase II Study of Irinotecan and Carboplatin in Metastatic and Relapsed Small Cell Lung Cancer  (contact: Christina Bachman, UCD)

18. Phase II Trial of Induction Chemoradiotherapy with Cisplatin/Etoposide Followed by Surgical Resection, Followed by Docetaxel, for Non-Small Cell Lung Cancer Involving the Superior Sulcus  (contact: Christine Reed, UCD)

19. Phase II Study of Docetaxel and OSI-774 in Solid Tumor Patients with an Emphasis on NSCLC Using Molecular Correlates As Potential Markers of Response  (contact: Christina Bachman, UCD)

20. Phase I/II Dose Intensification Study of Three Dimensional Conformal Radiation Therapy and Concurrent Chemotherapy for Patients with Inoperable Non-Small Cell Lung Cancer  (contact: Frances Lara, UCD)

21. Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, with Emphasis on Non-Small Cell Lung Cancer  (contact: Natasha Perkins, UCD)

22. Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors with an Emphasis on Non-Small Cell Lung Cancer  (contact: Christina Bachman, UCD)

23. Phase I Pilot Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer  (contact: Brian Kuest, UCD)

24. Phase I Study of Weekly Bortezomib (PS-341) and Weekly Topotecan in Advanced Solid Tumors, with Emphasis on Small Cell Lung Cancer  (contact: Christina Bachman, UCD)

25. Molecular Epidemiology Case-Series of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men  (contact: Rhoda Pineda, MGH; Maria Luisa Vargas, UCD)

26. EGFR Pathway Mutations in Lung Cancer Patient Tumors and Blood  (contact: Marilyn Robinson, UCD)

27. Ancillary, Lung Cancer Specimen Repository Protocol  (contact: Brian Kuest, UCD)
6. Melanoma

1. Randomized Phase II Trial of BAY 43-9006 with Either CCI-779 or R115777 in Metastatic Melanoma and Assessment of the Role of PET Imaging for Evaluation as an Early Indicator of Response (contact: Christine Reed, UCD)

7. Mesothelioma

1. Phase II Study of PXD 101 as Second-Line Therapy for Treatment of Patients with Malignant Pleural Mesothelioma (contact: Nicole Ekedah, UCD)

8. Prostatic Cancer

1. Phase III, Randomized, Open Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen Independent Prostate Cancer (contact: Natasha Perkins, UCD; Kirsten Babski or Lori Ried, SCC)
2. Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable–Risk Prostate Cancer (contact: Frances Lara, UCD)
3. Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMART vs. Androgen Suppression (AS) and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer (contact: Frances Lara, UCD)
4. Phase III Randomized Study of High Dose 3D-CRT Versus Standard Dose 3D-CRT in Patients Treated for Localized Prostate Cancer (contact: Frances Lara, UCD)
5. Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer, Phase III Brian Kuest (contact: Frances Lara, UCD)
6. Phase III Trial of Adjuvant Androgen Deprivation Versus Mitoxantrone + Prednisone + Androgen Deprivation in Selected High Risk Prostate Cancer Patients Following Radical Prostatectomy. (contact: Brian Kuest, UCD)
7. Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge®, APC8015) in Asymptomatic Subjects with Gleason Sum < 7, Metastatic, Androgen Independent Prostatic Adenocarcinomas (contact: Kirsten Babski or Lori Ried, SCC)
8. Phase II Trial of Daily, Oral Gleevec (Imatinib Mesylate,STI571) in Combination with Every-Three-Week Intravenous Docetaxel in Patients with Metastatic Hormone-Refractory Prostate Cancer (contact: Cammy Rieger, UCD)

9. Sarcoma

1. Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (contact: Natasha Perkins, UCD)
2. Groupwide Biology and Banking Study for Ewing Sarcoma (contact: Tracy Liu, UCD)
3. Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination with Standard Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors (contact: Tracy Liu, UCD)

UC Davis Cancer Center (UCD) 916-734-3089; Sutter Cancer Center (SCC) 916-454-6595; Mercy General Hospital (MGH) 916-453-4651

CancerPACT™ is presented by Lorenzen Cancer Foundation and UC Davis Cancer Center www.CancerPACT.org
4. Vincristine, Dactinomycin and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma (contact: Tracy Liu, UCD)

5. Osteosarcoma Biology Study (contact: Tracy Liu, UCD)

10. Urological Cancers

A. Bladder/Urethral Cancer

1. Phase II Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Recurrent or Metastatic Transitional Cell Carcinoma of the Urothelium (contact: Joan Houston, UCD)

2. Phase II Study of VEGF Trap in Patients with Recurrent or Metastatic Transitional Carcinoma of the Urothelium (contact: Nicole Ekedahl, UCD)

3. Phase I/II Study of E7389 Halichondrin B Analog in Metastatic Urothelial Tract Cancer and Renal Insufficiency (contact: Joan Houston, UCD)

B. Kidney Cancer

1. Phase II Trial of ZD1839 (IRESSA) and Pegylated Interferon Alfa 2B (PEG-Intron) in Unresectable or Metastatic Renal Cell Carcinoma (contact: Joan Houston, UCD)

2. Phase II Study of AZD2171 in Patients with Advanced Renal Cell Carcinoma (contact: Joan Houston, UCD)

3. National Wilms Tumor Late Effects Study (contact: Tracy Liu, UCD)

II. Hematological Cancers

1. Leukemia

1. Phase III Randomized Study of Different Combination Chemotherapy Regimens in Pediatric Patients with Newly Diagnosed Standard Risk B-precursor Acute Lymphoblastic Leukemia (contact: Tracy Liu, UCD)

2. Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy with or without Arsenic Trioxide as Initial Consolidation Therapy Followed by Intermittent Tretinoin Maintenance Therapy vs. Observation for Patients with Untreated Acute Promyelocytic Leukemia (contact: Tracy Liu, UCD)

3. Phase III Study of AlinC 17: Treatment for Patients with Low-Risk Acute Lymphoblastic Leukemia (contact: Tracy Liu, UCD)

4. Phase II Study of PXD 101 in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Following Up to Two Induction Regimens, or Patients Over the Age of 60 with Newly Diagnosed AML (contact: Joan Houston, UCD)

5. Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy (contact: Christine Reed, UCD)

6. Phase I Trial of R115777 in Relapsed, Refractory or High-Risk Acute Myeloid Leukemia (contact: Nicole Ekedahl, UCD)
7. Phase I Study of CCI-779 in Combination with Imatinib Mesylate in Chronic Myelogenous Leukemia (contact: Cammy Rieger, UCD)
8. Non Myeloablative Chemotherapy and Allogeneic Stem Cell Transplantation (Transplant Lite) in the Treatment of Selected Hematologic Malignancies (contact: Kirsten Babski or Lori Ried, SCC)
9. Cytogenetic Studies in Leukemia Patients (contact: Christine Reed, UCD)
10. Classification of Acute Lymphoblastic Leukemia (contact: Tracy Liu, UCD)
11. High Risk B-Precursor Acute Lymphoblastic Leukemia (contact: Tracy Liu, UCD)

2. Lymphoma

1. Phase III Trial of CHOP + Rituximab vs. CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphomas (contact: Christine Reed, UCD)
2. Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (with Possible Late Autologous Stem Cell Transplant) for Patients with Diffuse Aggressive Non-Hodgkin’s Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups. (contact: Christine Reed, UCD)
3. A Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma (contact: Tracy Liu, UCD)
4. Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin’s Lymphoma (contact: Joan Houston, UCD)

3. Myeloma

1. Phase IV Open Label Trial Using Velcade for the Re-Treatment of the Multiple Myeloma Patients Following an Initial Response to Velcade (contact: Rhoda Pineda, MGH)
2. Phase III Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-Myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma (contact: Christine Reed, UCD)
3. Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) and Autologous Peripheral Blood Stem Cell Supported Transplantation for Patients with AL Amyloidosis or High Risk (Greater Than or Equal to Age 70 or Poor Renal Function) Patients with Multiple Myeloma (A BMT Study) (contact: Christine Reed, UCD)
4. Myeloma Specimen Repository Protocol, Ancillary (contact: Christine Reed, UCD)